Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin

John S. Strauss, James J. Leyden, Anne W. Lucky, Donald P. Lookingbill, Lynn A. Drake, Jon Hanifin, Nicholas J. Lowe, Terry M. Jones, Daniel M. Stewart, Michael T. Jarratt, Irving Katz, David M. Pariser, Robert J. Pariser, Eduardo Tschen, Dan K. Chalker, Elyse S. Rafal, Ronald P. Savin, Harry L. Roth, Lawrence K. Chang, David J. BaginskiSteven Kempers, John McLane, Douglas Eberhardt, Eileen E. Leach, Graeme Bryce, Joseph Hong

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: Isotretinoin is a very effective drug for treating severe recalcitrant nodular acne. A new micronized formula of isotretinoin has been shown to be clinically equivalent to standard isotretinoin with improved bioavailability and minimal food effect. The safety profile of the micronized formulation has not been described previously. Objective: The objective of this article is to report the incidence and intensity, of adverse events found in a comparative double-blind efficacy study that showed clinical equivalence of the new micronized formulation of isotretinoin and the standard isotretinoin formulation (Accutane). Methods: Six hundred patients with severe recalcitrant nodular acne were treated with micronized isotretinoin (n = 300) under fasted conditions or standard isotretinoin (n = 300) under fed conditions. One cohort received single daily doses of 0.4 mg/kg of micronized isotretinoin without food and the other cohort received 1.0 mg/kg per day of standard isotretinoin in two divided doses with food. Adverse events were monitored during 20 weeks of drug therapy. Results: The proportion of adverse events in most body systems was generally lower in patients receiving micronized isotretinoin than in those receiving standard isotretinoin. Conclusion: Micronized isotretinoin appears to have a safety profile similar to that of standard isotretinoin and to carry a lower risk of mucocutaneous events and hypertriglyceridemia.

Original languageEnglish (US)
Pages (from-to)196-207
Number of pages12
JournalJournal of the American Academy of Dermatology
Volume45
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Isotretinoin
Acne Vulgaris
Safety
Food
Hypertriglyceridemia
Double-Blind Method
Biological Availability

ASJC Scopus subject areas

  • Dermatology

Cite this

Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne : A randomized trial comparing micronized isotretinoin with standard isotretinoin. / Strauss, John S.; Leyden, James J.; Lucky, Anne W.; Lookingbill, Donald P.; Drake, Lynn A.; Hanifin, Jon; Lowe, Nicholas J.; Jones, Terry M.; Stewart, Daniel M.; Jarratt, Michael T.; Katz, Irving; Pariser, David M.; Pariser, Robert J.; Tschen, Eduardo; Chalker, Dan K.; Rafal, Elyse S.; Savin, Ronald P.; Roth, Harry L.; Chang, Lawrence K.; Baginski, David J.; Kempers, Steven; McLane, John; Eberhardt, Douglas; Leach, Eileen E.; Bryce, Graeme; Hong, Joseph.

In: Journal of the American Academy of Dermatology, Vol. 45, No. 2, 2001, p. 196-207.

Research output: Contribution to journalArticle

Strauss, JS, Leyden, JJ, Lucky, AW, Lookingbill, DP, Drake, LA, Hanifin, J, Lowe, NJ, Jones, TM, Stewart, DM, Jarratt, MT, Katz, I, Pariser, DM, Pariser, RJ, Tschen, E, Chalker, DK, Rafal, ES, Savin, RP, Roth, HL, Chang, LK, Baginski, DJ, Kempers, S, McLane, J, Eberhardt, D, Leach, EE, Bryce, G & Hong, J 2001, 'Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin', Journal of the American Academy of Dermatology, vol. 45, no. 2, pp. 196-207. https://doi.org/10.1067/mjd.2001.115966
Strauss, John S. ; Leyden, James J. ; Lucky, Anne W. ; Lookingbill, Donald P. ; Drake, Lynn A. ; Hanifin, Jon ; Lowe, Nicholas J. ; Jones, Terry M. ; Stewart, Daniel M. ; Jarratt, Michael T. ; Katz, Irving ; Pariser, David M. ; Pariser, Robert J. ; Tschen, Eduardo ; Chalker, Dan K. ; Rafal, Elyse S. ; Savin, Ronald P. ; Roth, Harry L. ; Chang, Lawrence K. ; Baginski, David J. ; Kempers, Steven ; McLane, John ; Eberhardt, Douglas ; Leach, Eileen E. ; Bryce, Graeme ; Hong, Joseph. / Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne : A randomized trial comparing micronized isotretinoin with standard isotretinoin. In: Journal of the American Academy of Dermatology. 2001 ; Vol. 45, No. 2. pp. 196-207.
@article{c5a1ae43fa894c7fb288c44e54aa59e2,
title = "Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin",
abstract = "Background: Isotretinoin is a very effective drug for treating severe recalcitrant nodular acne. A new micronized formula of isotretinoin has been shown to be clinically equivalent to standard isotretinoin with improved bioavailability and minimal food effect. The safety profile of the micronized formulation has not been described previously. Objective: The objective of this article is to report the incidence and intensity, of adverse events found in a comparative double-blind efficacy study that showed clinical equivalence of the new micronized formulation of isotretinoin and the standard isotretinoin formulation (Accutane). Methods: Six hundred patients with severe recalcitrant nodular acne were treated with micronized isotretinoin (n = 300) under fasted conditions or standard isotretinoin (n = 300) under fed conditions. One cohort received single daily doses of 0.4 mg/kg of micronized isotretinoin without food and the other cohort received 1.0 mg/kg per day of standard isotretinoin in two divided doses with food. Adverse events were monitored during 20 weeks of drug therapy. Results: The proportion of adverse events in most body systems was generally lower in patients receiving micronized isotretinoin than in those receiving standard isotretinoin. Conclusion: Micronized isotretinoin appears to have a safety profile similar to that of standard isotretinoin and to carry a lower risk of mucocutaneous events and hypertriglyceridemia.",
author = "Strauss, {John S.} and Leyden, {James J.} and Lucky, {Anne W.} and Lookingbill, {Donald P.} and Drake, {Lynn A.} and Jon Hanifin and Lowe, {Nicholas J.} and Jones, {Terry M.} and Stewart, {Daniel M.} and Jarratt, {Michael T.} and Irving Katz and Pariser, {David M.} and Pariser, {Robert J.} and Eduardo Tschen and Chalker, {Dan K.} and Rafal, {Elyse S.} and Savin, {Ronald P.} and Roth, {Harry L.} and Chang, {Lawrence K.} and Baginski, {David J.} and Steven Kempers and John McLane and Douglas Eberhardt and Leach, {Eileen E.} and Graeme Bryce and Joseph Hong",
year = "2001",
doi = "10.1067/mjd.2001.115966",
language = "English (US)",
volume = "45",
pages = "196--207",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne

T2 - A randomized trial comparing micronized isotretinoin with standard isotretinoin

AU - Strauss, John S.

AU - Leyden, James J.

AU - Lucky, Anne W.

AU - Lookingbill, Donald P.

AU - Drake, Lynn A.

AU - Hanifin, Jon

AU - Lowe, Nicholas J.

AU - Jones, Terry M.

AU - Stewart, Daniel M.

AU - Jarratt, Michael T.

AU - Katz, Irving

AU - Pariser, David M.

AU - Pariser, Robert J.

AU - Tschen, Eduardo

AU - Chalker, Dan K.

AU - Rafal, Elyse S.

AU - Savin, Ronald P.

AU - Roth, Harry L.

AU - Chang, Lawrence K.

AU - Baginski, David J.

AU - Kempers, Steven

AU - McLane, John

AU - Eberhardt, Douglas

AU - Leach, Eileen E.

AU - Bryce, Graeme

AU - Hong, Joseph

PY - 2001

Y1 - 2001

N2 - Background: Isotretinoin is a very effective drug for treating severe recalcitrant nodular acne. A new micronized formula of isotretinoin has been shown to be clinically equivalent to standard isotretinoin with improved bioavailability and minimal food effect. The safety profile of the micronized formulation has not been described previously. Objective: The objective of this article is to report the incidence and intensity, of adverse events found in a comparative double-blind efficacy study that showed clinical equivalence of the new micronized formulation of isotretinoin and the standard isotretinoin formulation (Accutane). Methods: Six hundred patients with severe recalcitrant nodular acne were treated with micronized isotretinoin (n = 300) under fasted conditions or standard isotretinoin (n = 300) under fed conditions. One cohort received single daily doses of 0.4 mg/kg of micronized isotretinoin without food and the other cohort received 1.0 mg/kg per day of standard isotretinoin in two divided doses with food. Adverse events were monitored during 20 weeks of drug therapy. Results: The proportion of adverse events in most body systems was generally lower in patients receiving micronized isotretinoin than in those receiving standard isotretinoin. Conclusion: Micronized isotretinoin appears to have a safety profile similar to that of standard isotretinoin and to carry a lower risk of mucocutaneous events and hypertriglyceridemia.

AB - Background: Isotretinoin is a very effective drug for treating severe recalcitrant nodular acne. A new micronized formula of isotretinoin has been shown to be clinically equivalent to standard isotretinoin with improved bioavailability and minimal food effect. The safety profile of the micronized formulation has not been described previously. Objective: The objective of this article is to report the incidence and intensity, of adverse events found in a comparative double-blind efficacy study that showed clinical equivalence of the new micronized formulation of isotretinoin and the standard isotretinoin formulation (Accutane). Methods: Six hundred patients with severe recalcitrant nodular acne were treated with micronized isotretinoin (n = 300) under fasted conditions or standard isotretinoin (n = 300) under fed conditions. One cohort received single daily doses of 0.4 mg/kg of micronized isotretinoin without food and the other cohort received 1.0 mg/kg per day of standard isotretinoin in two divided doses with food. Adverse events were monitored during 20 weeks of drug therapy. Results: The proportion of adverse events in most body systems was generally lower in patients receiving micronized isotretinoin than in those receiving standard isotretinoin. Conclusion: Micronized isotretinoin appears to have a safety profile similar to that of standard isotretinoin and to carry a lower risk of mucocutaneous events and hypertriglyceridemia.

UR - http://www.scopus.com/inward/record.url?scp=17844374318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844374318&partnerID=8YFLogxK

U2 - 10.1067/mjd.2001.115966

DO - 10.1067/mjd.2001.115966

M3 - Article

C2 - 11464180

AN - SCOPUS:17844374318

VL - 45

SP - 196

EP - 207

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -